phrykt

Sagimet Biosciences Inc. (SGMT): who owns it and who trades it

As of Nov 16, 2026, SGMT insiders reported 10 open-market sales worth $4.9M and no purchases in the last 12 months, with 6% of the sale value made under pre-set 10b5-1 plans. The largest seller was George Kemble (Chair), with $4.2M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Sagimet Biosciences

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns SGMT

122 funds and institutions reported SGMT shares worth $396M at the end of Q2 2026. The largest holder is BlackRock, Inc. with $50.8M.

10 largest owners, by value

BlackRock, Inc.$50.8M
Balyasny Asset Management L.P.$28M
Woodline Partners LP$23.2M
Silverarc Capital Management, LLC$22.6M
Vanguard Capital Management LLC$19.8M
Caligan Partners LP$19.3M
Bvf Inc$19.3M
Affinity Asset Advisors, LLC$19.3M
Federated Hermes, Inc.$16.1M
Great Point Partners LLC$15.7M

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.6.58M–$50.8M+722%
Balyasny Asset Management L.P.3.63M–$28MNew
Woodline Partners LP3.00M–$23.2M+200%
Silverarc Capital Management, LLC2.93M–$22.6MNew
Vanguard Capital Management LLC2.57M–$19.8M+134%
Caligan Partners LP2.50M–$19.3MNew
Bvf Inc2.50M–$19.3MNew
Affinity Asset Advisors, LLC2.50M–$19.3M+188%
Federated Hermes, Inc.2.09M–$16.1M+267085%
Great Point Partners LLC2.03M–$15.7MNew
State Street Corp2.00M–$15.4M+1449%
Saturn V Capital Management LP1.48M–$11.4MNew
Geode Capital Management, LLC1.44M–$11.2M+367%
Blue Owl Capital Holdings LP1.26M–$9.7M+278%
Baker Bros. Advisors LP952,996–$7.4MNo change
Millennium Management LLC937,025–$7.2M+9%
Aberdeen Group plc847,700–$6.6MNew
Goldman Sachs Group Inc759,086–$5.9M+348%
Hhlr Advisors, Ltd.724,800–$5.6MNo change
Ameriprise Financial Inc581,217–$4.5MNew

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, SGMT insiders reported $0 of open-market purchases and $4.9M of sales. 6% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$4.9M
10 trades, 5 people
Sales under a 10b5-1 plan
6%
Share of sale value
Latest trade
Aug 14, 2026
Filed Aug 17, 2026

Purchases and sales by month

$3.8M$3.8MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 14, 2026George KembleDirectorSale350,987$10.23$3.6MForm 4
Aug 11, 2026George KembleDirectorSale20,206$9.95$201KForm 4
Jul 20, 2026David HappelCEOSale64,051$7.76$497KForm 4
Jul 20, 2026Elizabeth RozekChief Legal & Admin. OffSale10,545$7.76$81.8KForm 4
Jul 20, 2026George KembleDirectorSale18,844$7.46$141KForm 4
Feb 10, 2026David HappelCEOSale12,101$5.36$64.9KForm 4
Feb 10, 2026Thierry ChaucheCFOSale1,312$5.36$7KForm 4
Feb 10, 2026Eduardo Bruno MartinsChief Medical OfficerSale3,640$5.36$19.5KForm 4
Feb 10, 2026Elizabeth RozekChief Legal & Admin. OffSale2,622$5.36$14.1KForm 4
Nov 20, 2025George KembleChairSale plan37,688$7.69$290KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
George KembleExecutive Chairman, Director–$4.2MAug 14, 2026
David HappelPresident & CEO, Director–$562KJul 20, 2026
Elizabeth RozekChief Legal & Admin. Officer–$95.9KJul 20, 2026
Eduardo Bruno MartinsChief Medical Officer–$19.5KFeb 10, 2026
Thierry ChaucheChief Financial Officer–$7KFeb 10, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

SGMT short interest

12.17M SGMT shares are sold short. Over the last 12 reports the number of shares short went up 189%.

As of Oct 30, 2026, 12.17M SGMT shares were sold short, up 5.6% from the report before. At the average daily volume of 1.16M shares, buying them all back would take about 10.5 trading days (days to cover).

Shares short

12.17MMay 15Oct 3013.37M

Days to cover

10.5May 15Oct 3018.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202612.17M–+6%1.16M10.5
Oct 15, 202611.53M–+3%1.40M8.2
Sep 30, 202611.19M–+9%1.67M6.7
Sep 15, 202610.26M–+1%971,53310.6
Aug 31, 202610.11M–-14%1.06M9.6
Aug 14, 202611.75M–+1%1.71M6.9
Jul 31, 202611.60M–+19%711,09016.3
Jul 15, 20269.74M–+18%1.06M9.2
Jun 30, 20268.25M–+42%2.10M3.9
Jun 15, 20265.83M–+21%646,9379.0
May 29, 20264.80M–+14%826,1485.8
May 15, 20264.21M–-7%985,3804.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Sagimet Biosciences company events

Sagimet Biosciences filed 17 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Oct 22, 2026.

  1. Oct 22, 2026AnnouncementShared information with investors. Filing
  2. Oct 1, 2026AgreementSagimet Biosciences Inc. entered into an underwriting agreement with Leerink Partners LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC as representatives of the several underwriters named therein relating to an underwritten offering of (i) 8,750,010 shares of the Company’s Series A… Filing
  3. Sep 30, 2026AnnouncementThe Company issued a press release announcing positive 52-week results from the Phase 3 ASC40-304 open-label extension clinical trial of denifanstat in patients with moderate to severe acne vulgaris, conducted by license partner Ascletis BioScience Co. Ltd. in China. Filing
  4. Aug 13, 2026AnnouncementSagimet Biosciences Inc. announced that the U.S. Food and Drug Administration cleared the Investigational New Drug application and issued a “Study May Proceed” letter for the Company’s Phase 3 clinical trial of fatty acid synthase inhibitor denifanstat in moderate to severe acne. Filing
  5. Aug 11, 2026ResultsReleased financial results. Filing
  6. Jul 21, 2026AnnouncementShared information with investors. Filing
  7. Jun 12, 2026LeadershipTim Walbert, a member of the Board of Directors of Sagimet Biosciences Inc., tendered his resignation from the Board, effective as of June 12, 2026. Filing
  8. Jun 3, 2026LeadershipThe Compensation Committee of the Board of Directors of Sagimet Biosciences Inc. and the Board, as applicable, granted options to purchase shares of the Company’s Series A common stock, par value $0.0001 per share, and performance-based restricted stock units to David Happel, the Company’s… Filing
  9. May 12, 2026ResultsReleased financial results. Filing
  10. Apr 28, 2026AgreementSagimet Biosciences Inc. entered into an underwriting agreement with Leerink Partners LLC, TD Securities (USA) LLC, and Guggenheim Securities, LLC as representatives of the several underwriters named therein relating to an underwritten offering of 29,166,700 shares of the Company’s Series A common… Filing
  11. Apr 27, 2026AnnouncementShared information with investors. Filing
  12. Apr 27, 2026AnnouncementThe Company issued a press release announcing certain strategic and corporate updates. Filing
  13. Apr 21, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Filing
  14. Mar 11, 2026ResultsReleased financial results. Filing
  15. Feb 2, 2026AnnouncementShared information with investors. Filing
  16. Dec 18, 2025AnnouncementThe Company issued a press release announcing positive results in the Phase 1 pharmacokinetic trial of a combination of its oral once-daily fatty acid synthase inhibitor, denifanstat, and a thyroid hormone receptor beta agonist, resmetirom. Filing
  17. Dec 17, 2025AnnouncementSagimet Biosciences Inc. issued a press release announcing its entry into a license agreement with Assia Chemical Industries Ltd., doing business as TAPI Technology & API Services, a subsidiary of Teva Pharmaceutical Industries Ltd. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Sagimet Biosciences financials

Famous investors that hold SGMT

4 of the 50 well-known investors we track reported holding SGMT in their latest 13F filing. The largest position is Israel Englander's, worth $4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026406,857$4M0.0%-57%
Ken Griffin · Citadel AdvisorsQ3 2026133,079$1.3M0.0%+27%
Jim Simons · Renaissance TechnologiesQ3 202689,700$886K0.0%-74%
Steve Cohen · Point72 Asset ManagementQ3 202635,629$352K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named SGMT in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Woodline Partners LP13G5.1%
Nov 16, 2026Woodline Partners LP13G5.1%
Nov 16, 2026BALYASNY ASSET MANAGEMENT L.P.13G/A9.0%
Nov 16, 2026BALYASNY ASSET MANAGEMENT L.P.13G/A9.0%
Nov 13, 2026SilverArc Capital Management, LLC13G6.1%
Nov 13, 2026SilverArc Capital Management, LLC13G6.1%
Oct 7, 2026Commodore Capital LP13G7.6%
Oct 7, 2026Commodore Capital LP13G7.6%

Questions about Sagimet Biosciences Inc. (SGMT) stock

Who owns the most SGMT stock?

The largest reported owner of Sagimet Biosciences Inc. (SGMT) is BlackRock, Inc.. In total, 122 funds and institutions reported holding SGMT at the end of Q2 2026. See the largest owners.

Are SGMT insiders buying or selling?

In the last 12 months, SGMT insiders reported no open-market purchases and 10 sales worth $4.9M. The latest trade was on Aug 14, 2026. See every trade.

What is the short interest in SGMT?

As of Oct 30, 2026, 12.17M SGMT shares were sold short, up 5.6% from the report before. At the average daily volume of 1.16M shares, buying them all back would take about 10.5 trading days (days to cover). See the history.

Which famous investors hold SGMT?

4 of the 50 well-known investors we track reported SGMT in their latest 13F filing, including Israel Englander, Ken Griffin, Jim Simons. The largest position is worth $4M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.